PMID- 35124914
OWN - NLM
STAT- MEDLINE
DCOM- 20220208
LR  - 20221207
IS  - 1819-2718 (Electronic)
IS  - 1025-9589 (Linking)
VI  - 33
IP  - 4
DP  - 2021 Oct-Dec
TI  - Comparison Of Efficacy And Safety Profile Of Empagliflozin Versus Dapagliflozin 
      As Add On Therapy In Type 2 Diabetic Patients.
PG  - 593-597
AB  - BACKGROUND: SGLT-2 (sodium-glucose cotransporter-2) inhibitors are a novel class 
      of oral hypoglycemic agents for the management of type 2 diabetes mellitus 
      (T2DM). Herein, we aimed to assess the efficacy and safety profile of 
      empagliflozin versus dapagliflozin in type 2 diabetic patients. METHODS: In this 
      randomized controlled trial, type 2 diabetic patients with inadequate glycaemic 
      control HbA1c 7.5-11% with different first line anti diabetic medications were 
      randomly divided in to two groups. Group A were given tablet Empagliflozin 25 mg 
      while Group B were given tablet Dapagliflozin 10mg over a period of 12 weeks. The 
      primary end point was to measures efficacy profile in terms of changes in body 
      weight, BMI, fasting blood sugar and HbA1c. The secondary end point was to 
      determine safety and tolerability profile. RESULTS: After 12 weeks of treatment 
      body weight was reduced significantly in both groups empagliflozin - 2.9+/-6.4 kg 
      (p(=)0.002) versus dapagliflozin -1.7+/-2.4 (p(=)0.007). However, comparison between 
      two groups was non-significant (p(=)0.032). FBS was reduced in both study groups 
      empagliflozin - 75.6+/-43.5 mg/dl versus dapagliflozin -63.5 +/- 60.5 mg/dl with 
      p<0.01. However, empagliflozin caused a significant reduction in fasting blood 
      sugar as compared to dapagliflozin (p(=)0.001). HbA1c was also significantly 
      reduced in both groups empagliflozin -1.7+/-0.9% versus dapagliflozin -1.2+/-1.4% 
      with p < 0.01 . However, empagliflozin caused a more significant reduction in 
      HbA1c as compared to dapagliflozin (p(=)0.002). The tolerability profile of both 
      drugs was quite good and no major adverse effects were reported in both study 
      groups. However minor adverse effects were observed in both study groups. There 
      was low risk of urinary and genital infection with empagliflozin (2.34% & 3.1%) 
      as compared to dapagliflozin (7.08% and 8.66%) with p-value 0.003 and 0.005 
      respectively. CONCLUSIONS: Both empagliflozin and dapagliflozin has excellent 
      efficacy and safety profile. They can be used as add on therapy in type 2 
      diabetic patients.
FAU - Hussain, Mazhar
AU  - Hussain M
AD  - Department of Pharmacology, Sheikh Zayed Medical College and Hospital, Rahim Yar 
      Khan, Pakistan.
FAU - Atif, Moazzam
AU  - Atif M
AD  - Department of Pharmacology, Sheikh Zayed Medical College and Hospital, Rahim Yar 
      Khan, Pakistan.
FAU - Babar, Muhammad
AU  - Babar M
AD  - Department of Medicine, Sheikh Zayed Medical College and Hospital, Rahim Yar 
      Khan, Pakistan.
FAU - Akhtar, Lubna
AU  - Akhtar L
AD  - Department of Pharmacology, Sheikh Zayed Medical College and Hospital, Rahim Yar 
      Khan, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Pakistan
TA  - J Ayub Med Coll Abbottabad
JT  - Journal of Ayub Medical College, Abbottabad : JAMC
JID - 8910750
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Glucosides
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Dapagliflozin; Empagliflozin; BMI; HbA1c
OT  - Safety Profile; Adverse Effect
EDAT- 2022/02/07 06:00
MHDA- 2022/02/09 06:00
CRDT- 2022/02/06 20:41
PHST- 2022/02/06 20:41 [entrez]
PHST- 2022/02/07 06:00 [pubmed]
PHST- 2022/02/09 06:00 [medline]
AID - 9089/3174 [pii]
PST - ppublish
SO  - J Ayub Med Coll Abbottabad. 2021 Oct-Dec;33(4):593-597.